Online inquiry

IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ4313MR)

This product GTTS-WQ4313MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets C1S gene. The antibody can be applied in Cold agglutinin disease (CAD) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001346850.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 716
UniProt ID P09871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ4313MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7164MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ6933MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ENIA11
GTTS-WQ15807MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ9045MR IVTScrip™ mRNA-Anti-FLT1, IMC-18F1(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMC-18F1
GTTS-WQ12142MR IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MORAb-004
GTTS-WQ11900MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ4600MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ4096MR IVTScrip™ mRNA-Anti-oxLDL, BI-204(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BI-204
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW